HONG KONG – Biotech stocks have generally avoided the lackluster performance that has characterized stocks in China and Hong Kong in the last quarter. A spate of acquisitions and greater investments in research and development have helped push forward an ongoing consolidation of the market and supported share prices.
HONG KONG – Biotech stocks have generally avoided the lackluster performance that has characterized stocks in China and Hong Kong in the last quarter. A spate of acquisitions and greater investments in research and development have helped push forward an ongoing consolidation of the market and supported share prices.
HONG KONG – A leading Chinese biotech company has plans to sell almost half the shares of its vaccine manufacturing subsidiary and invest $30 million in a biopharmaceutical distributor.
HONG KONG – A leading Chinese biotech company has plans to sell almost half the shares of its vaccine manufacturing subsidiary and invest $30 million in a biopharmaceutical distributor.
HONG KONG – A Chinese biotech company has plans to further explore the potential of immuno-oncology products through a licensing deal with a U.S. pharma company dedicated to oncology.
HONG KONG – A Chinese biotech company has plans to further explore the potential of immuno-oncology products through a licensing deal with a U.S. pharma company dedicated to oncology. The push could put Lee's Pharmaceutical Holdings as a leader in that particular class of drugs in China, a class that has enormous potential.
HONG KONG – An American pharmaceutical firm is working with a Japanese biotech company to combine two antibodies into a more effective immunotherapy for solid tumors.
HONG KONG – An American pharmaceutical firm is working with a Japanese biotech company to combine two antibodies into a more effective immunotherapy for solid tumors.
HONG KONG – Following an approval in India, a U.S. biosimilars maker has partnered with its investor in China to expand its presence in emerging markets.
HONG KONG – Following an approval in India, a U.S. biosimilars maker has partnered with its investor in China to expand its presence in emerging markets.
